Results 81 to 90 of about 46,143 (249)

Thrombotic Thrombocytopenic Purpura Revisited: Upshaw Schulman Syndrome in a 20-Year-Old Male [PDF]

open access: yes, 2012
Case Report A 20-year-old male with no significant past medical history presented to an outside hospital with a two-week history of progressive fatigue, malaise and decreased appetite. Prior to these events, he had been in his usual state of health with
Peiris, MD, Niluk, Wang, MD, Judy
core   +2 more sources

Evaluating the appropriateness of fresh frozen plasma transfusions in two tertiary teaching hospitals

open access: yesTransfusion Medicine, EarlyView.
Abstract Background Despite efforts to standardise practice using evidence‐based guidelines, fresh frozen plasma (FFP) remains the blood component most frequently prescribed inappropriately. This study assessed the appropriateness of FFP transfusion in two tertiary teaching hospitals and analysed the characteristics of appropriate and inappropriate ...
Jongmin Kim   +3 more
wiley   +1 more source

Plasma levels of S100A8/A9, histone/DNA complexes, and cell‐free DNA predict adverse outcomes of immune thrombotic thrombocytopenic purpura

open access: yesJournal of Thrombosis and Haemostasis, 2020
Immune thrombotic thrombocytopenic purpura (iTTP) is a life‐threatening blood disorder, primarily resulting from autoantibodies against ADAMTS13. Infection or inflammation often precedes acute iTTP.
Jingrui Sui   +6 more
semanticscholar   +1 more source

Daratumumab for immune thrombotic thrombocytopenic purpura

open access: yesBlood Advances, 2021
Key Points Treatment of iTTP with daratumumab leads to disappearance of ADAMTS13 inhibitor and restoration of normal ADAMTS13 activity. Targeting of plasma cells with daratumumab is a new treatment option in relapsing and refractory iTTP.
J. van den Berg   +6 more
semanticscholar   +1 more source

Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura.

open access: yesBlood, 2018
Preemptive rituximab infusions prevent relapses in immune thrombotic thrombocytopenic purpura (iTTP) by maintaining normal ADAMTS13 activity. However, the long-term outcome of these patients and the potential adverse events of this strategy need to be ...
M. Jestin   +26 more
semanticscholar   +1 more source

A rare case of hereditary thrombotic thrombocytopenic purpura in a toddler

open access: yesLiječnički vjesnik, 2023
Hereditary thrombotic thrombocytopenic purpura (hTTP) is a thrombotic microangiopathy caused by pathogenic variants in the ADAMTS13 gene resulting in highly reduced activity of von Willebrand factor-cleaving metalloprotease.
Ozana Jakšić   +2 more
doaj   +1 more source

Modern concepts of the platelet in health and disease [PDF]

open access: yes, 1962
Thesis (M.D.)--Boston ...
Estes, J. Worth
core  

Cerebral fat embolism syndrome mimicking thrombotic thrombocytopenic purpura in a patient with Hemoglobin SC disease [PDF]

open access: yes, 2016
Case Presentation A 54 year‐old man with hemoglobin SC disease (HbSC) and a history of substance abuse presented to the Emergency Department from a nursing home with two days of progressive weakness, shortness of breath, and lower back pain.
Devnani, Rohit   +2 more
core   +1 more source

Endothelial Glycocalyx: The Missing Link Between Angiogenic Imbalance in Preeclampsia and Systemic Inflammation in HELLP Syndrome

open access: yesComprehensive Physiology, Volume 15, Issue 4, August 2025.
Endothelial glycocalyx may be the missing link between angiogenic factors, inflammatory regulation, and endothelial maternal dysfunction in early‐onset preeclampsia and HELLP syndrome. ABSTRACT The pathophysiology of preeclampsia and HELLP syndrome relies on systemic vascular endothelial dysfunction, resulting from angiogenic imbalance due to abnormal ...
Anthony Atallah   +4 more
wiley   +1 more source

Sunitinib Induced Thrombotic Thrombocytopenic Purpura in addition to Severe Hypothyroidism: A Case Report and Review of the Literature

open access: yesCase Reports in Medicine, 2014
Introduction. Sunitinib malate is an oral multitargeting tyrosine kinase inhibitor approved for the first line treatment of metastatic renal cell carcinoma.
Imane El Dika   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy